SOURCE: Hansen Medical, Inc.

May 12, 2008 17:03 ET

Hansen Medical to Present at Upcoming Investor Conferences

MOUNTAIN VIEW, CA--(Marketwire - May 12, 2008) - Hansen Medical, Inc. (NASDAQ: HNSN), a developer of new generation robotic technology for accurate and stable control of catheter movement in 3D during cardiac procedures, announced today that it will be participating in upcoming investor conferences.

The company will be presenting at the JMP Securities Seventh Annual Research Conference being held May 19-21, 2008 at The Ritz-Carlton, San Francisco. President and Chief Operating Officer, Gary Restani, will provide a general company overview on Monday, May 19, 2008 at 1:30 p.m. PDT.

The company will also be presenting at the Citi Investment Research Global Healthcare Conference being held May 21-22, 2008 at The Hilton New York. Co-Founder and Chief Executive Officer, Fred Moll, M.D., will provide a general company overview on Wednesday, May 21, 2008 at 9:30 a.m. EDT.

Hansen Medical will provide live audio webcasts of each presentation. Interested parties may access the live webcasts by visiting the investor relations section of Hansen Medical's web site at A replay of the webcasts will be available at the site after the live presentation.

About Hansen Medical, Inc.

Hansen Medical, Inc., based in Mountain View, Calif., develops products and technology using robotics for the accurate positioning, manipulation and control of catheters and catheter-based technologies. Its first product, the Sensei Robotic Catheter system, is a robotic navigation system that enables clinicians to place mapping catheters in hard-to-reach anatomical locations within the heart easily, accurately and with stability during complex cardiac arrhythmia procedures. The Sensei system is compatible with fluoroscopy, ultrasound, 3D surface map and patient electrocardiogram data and was cleared by the U.S. Food & Administration (FDA) in May 2007 for manipulation and control of certain mapping catheters in Electrophysiology (EP) procedures. In the European Union, the Sensei system is cleared for use during EP procedures, such as guiding catheters in the treatment of atrial fibrillation (AF).

The safety and effectiveness of the Sensei system for use with cardiac ablation catheters in the treatment of cardiac arrhythmias, including AF, have not been established. Additional information can be found at

Contact Information